Logo Medical XPRT
Companies
Products
Services
Software
Training
Applications
Sign in
List your business

Advertising options
  1. Home
  2. news
  3. drug development pipeline
Show results for
Products
Services

Companies

News
Articles

Refine by
Date

  • This Year
  • Older

Drug Development Pipeline Articles & Analysis

10 news found

Biopharma PEG Achieves FDA DMF Approval for HZ-PEG-HZ

Biopharma PEG Achieves FDA DMF Approval for HZ-PEG-HZ

Watertown, MA - June 29, 2025 - Biopharma PEG, a leading innovator in high-quality polyethylene glycol (PEG) derivatives, today announced it has successfully obtained Drug Master File (DMF) approval from the U.S. Food and Drug Administration (FDA) for its self-developed HZ-PEG-HZ (1K) product. ...

ByBiopharma PEG Scientific Inc


Protheragen-ING AI-Pharma’s AI-Powered Drug Discovery and Design Platform—A Paradigm Shift in Drug Development

Protheragen-ING AI-Pharma’s AI-Powered Drug Discovery and Design Platform—A Paradigm Shift in Drug Development

In the ever-evolving landscape of pharmaceutical research and development, the demand for innovative and efficient drug discovery methods is more pressing than ever. ...

ByProtheragen-ING


Carcinotech and CELLINK Enter a Partnership to Develop and Commercialize Protocols for Cancer Models to Provide Improved Speed and Accuracy in the Drug Development Processes

Carcinotech and CELLINK Enter a Partnership to Develop and Commercialize Protocols for Cancer Models to Provide Improved Speed and Accuracy in the Drug Development Processes

Carcinotech and CELLINK are pleased to announce a collaborative partnership to develop and commercialize protocols for the biofabrication of 3D bioprinted tumor models based on cancer cell lines that improve accuracy and rapidly speed up drug development processes, driving down development costs and enabling an improved output. ...

ByCELLINK


AI promises a new future of drug discovery for rare diseases

AI promises a new future of drug discovery for rare diseases

Despite affecting over 400 million people around the globe, rare diseases have largely been overlooked by traditional drug discovery methods. This is because traditional model often prioritise disease areas where there is a greater understanding of the basic underlying biology and which, in turn, generally come from the larger patient populations associated with more common diseases. This is part ...

ByHealx Ltd.


NEC OncoImmunity Acquires VAXIMM’s Neoantigen Vaccine Development Assets

NEC OncoImmunity Acquires VAXIMM’s Neoantigen Vaccine Development Assets

” The transaction expands NEC’s neoantigen drug development pipeline by broadening its focus into several compelling therapeutic areas with high unmet medical need. ...

ByNEC OncoImmunity AS 


Atomwise Adds Pharma Luminaries to Board of Directors and Scientific Advisory Board

Atomwise Adds Pharma Luminaries to Board of Directors and Scientific Advisory Board

Atomwise has strengthened its drug discovery and development expertise by expanding its Board of Directors and creating a Scientific Advisory Board (SAB). ...

ByAtomwise Inc.


Atomwise Named to Fast Company’s Annual List of the World’s Most Innovative Companies for 2021

Atomwise Named to Fast Company’s Annual List of the World’s Most Innovative Companies for 2021

Atomwise was recognized for its unmatched AI platform, AtomNet®?, as well as its growing pipeline and portfolio of partnerships and joint ventures tackling some of the most challenging targets in small molecule drug development. ...

ByAtomwise Inc.


Atomwise and FutuRx Launch A2i Therapeutics - A New Immuno-Oncology Company Funded by Leading Biopharma VCs and the Israeli Innovation Authority

Atomwise and FutuRx Launch A2i Therapeutics - A New Immuno-Oncology Company Funded by Leading Biopharma VCs and the Israeli Innovation Authority

“Atomwise is at the forefront of AI-driven drug discovery, and this partnership with FutuRx will help pursue difficult disease targets and significantly boost the Israeli AI drug discovery and bio-convergence ...

ByAtomwise Inc.


Atomwise Receives a $2.3M Grant to Develop New Therapies for Drug Resistant Malaria and Tuberculosis

Atomwise Receives a $2.3M Grant to Develop New Therapies for Drug Resistant Malaria and Tuberculosis

” About the Medicines for Malaria Venture Medicines for Malaria Venture (MMV) is a leading product development partnership (PDP) in the field of antimalarial drug research and development. ...

ByAtomwise Inc.


GC Pharma Taps Small Molecule AI Expert Atomwise to Expand Hemophilia Franchise

GC Pharma Taps Small Molecule AI Expert Atomwise to Expand Hemophilia Franchise

Atomwise, the leader in using artificial intelligence (AI) for small molecule drug discovery, announced today a partnership with GC Pharma (KRX: 006280), a South Korean biopharmaceutical company formerly known as Green Cross Corporation, to discover and develop novel hemophilia therapies. ...

ByAtomwise Inc.

  • Previous
  • Next
Need help finding the right suppliers?Try XPRT Sourcing. Let the XPRTs do the work for you
Back to top
About

Channels

Solutions

  • Industry Products
  • Industry Software
  • Industry Training
  • Industry Services
  • Industry Applications

Latest

  • Industry News
  • Industry Events

Publications

  • Industry Articles
  • Industry Books
  • Industry Magazines
  • Industry Downloads
  • Industry Videos

Companies

  • Industry Companies

  • FAQs
  • Company sitemap
  • Category sitemap
is part of XPRT Media All Rights Reserved.
Terms
Privacy
  • Medical XPRT RSS List
Our sites:
Environmental XPRT
Agriculture XPRT
Energy XPRT
XPRT